Polyrizon Shares Surge on Impending Clinical Trial

Dow Jones12-19

By Sarina Isaacs

Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year.

The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32.

The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said.

The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards.

Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month.

Write to Sarina Isaacs at sarina.isaacs@wsj.com

(END) Dow Jones Newswires

December 18, 2024 11:02 ET (16:02 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492913875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492913875","market":"us","top_or_hot":-1,"title":"Polyrizon Shares Surge on Impending Clinical Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sarina Isaacs \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year. \n</p>\n<p>\n  The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32. \n</p>\n<p>\n  The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said. \n</p>\n<p>\n  The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards. \n</p>\n<p>\n  Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sarina Isaacs at sarina.isaacs@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 11:02 ET (16:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polyrizon Shares Surge on Impending Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyrizon Shares Surge on Impending Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 00:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sarina Isaacs \n\n\n \n\n\n  Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year. \n\n\n  The stock on ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRZ","symbol_name":"Polyrizon Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492913875","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492913875","pubTimestamp":1734537720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year.The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32.The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said.The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards.Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRZ":"Polyrizon Ltd."},"translate_title":"Polyrizon股价因即将进行的临床试验而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":0.9},"content_text":"By Sarina Isaacs \n\n\n \n\n\n  Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year. \n\n\n  The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32. \n\n\n  The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said. \n\n\n  The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards. \n\n\n  Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month. \n\n\n \n\n\n  Write to Sarina Isaacs at sarina.isaacs@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 11:02 ET (16:02 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492913875"}